摘要
目的探讨沙库巴曲缬沙坦联合左西孟旦对冠心病合并慢性心力衰竭患者的临床疗效。方法选取2019年1月至2021年3月在郑州人民医院治疗的110例冠心病合并慢性心力衰竭患者作为研究对象,根据治疗方案分为对照组(55例)和观察组(55例)。两组患者均接受常规治疗,对照组在此基础上接受沙库巴曲缬沙坦钠药物治疗,观察组接受沙库巴曲缬沙坦钠联合左西孟旦治疗。治疗前后采用美国纽约心脏病学会分级标准对两组患者心功能改善情况进行评价,采用超声心动图检测两组患者左心室射血分数(LVEF)、左室舒张末期内径(LVEDD)和舒张早期峰值充盈速度(E峰)/舒张晚期峰值充盈速度(A峰)等参数,并采用酶联免疫吸附测定法检测脑钠肽(BNP)和可溶性生长刺激表达基因2蛋白(sST2)等生化标志物水平。结果观察组患者心功能改善率(94.55%)高于对照组(81.82%),差异有统计学意义(P<0.05);两组患者治疗后各超声心动图参数指标均有改善,且观察组LVEF和E峰/A峰高于对照组,LVEDD低于对照组,差异有统计学意义(P<0.05);两组患者治疗后血清BNP和sST2等各生化标志物均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。结论沙库巴曲缬沙坦联合左西孟旦治疗可以提高冠心病合并慢性心力衰竭患者心功能,促进超声心动图参数和血清生化指标的改善。
Objective To explore the clinical efficacy of sacubitril and valsartan combined with levosimendan in patients with coronary heart disease and chronic heart failure.Methods A total of 110 patients with coronary heart disease and chronic heart failure treated in Zhengzhou People’s Hospital from January 2019 to March 2021 were selected as the research objects,and were divided into the control group(55 cases)and the observation group(55 cases)according to the treatment plan.Both groups were given conventional treatment,the control group was treated with sacubitril and valsartan sodium on this basis,and the observation group was treated with sacubitril and valsartan sodium combined with levosimendan.Before and after treatment,the improvement of cardiac function was evaluated by New York cardiology society classification standard.Before and after treatment,the parameters of left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD)and early diastolic peak flling velocity(E peak)/late diastolic peak flling velocity(A peak)were detect by echocardiography.Before and after treatment,the biochemical markers of brain natriuretic peptide(BNP)and soluble growth stimulation expression gene 2 protein(sST2)were detected by enzyme linked immunosorbent assay.Results The improvement rate of cardiac function in the observation group(94.55%)was higher than that in the control group(81.82%)(P<0.05).After treatment,the echocardiographic parameters in the two groups were improved,LVEF and E/A in the observation group were higher than those in the control group,and LVEDD was lower than that in the control group(P<0.05).After treatment,the serum biochemical markers of BNP and sST2 in the two groups were reduced,and the above indexes in the observation group were lower than those in the control group(P<0.05).Conclusion The treatment of sacubitril and valsartan combined with levosimendan could improve the cardiac function of patients with coronary heart disease and chronic heart failure,and promote the improvement of echocardiographic parameters and serum biochemical indicators.
作者
张力俨
赵友民
张塬坤
ZHANG Liyan;ZHAO Youmin;ZHANG Yuankun(Department of Cardiology,Zhengzhou People’s Hospital,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2022年第6期1093-1096,共4页
Henan Medical Research
关键词
冠心病
慢性心力衰竭
沙库巴曲缬沙坦
左西孟旦
心功能
生化标志物
coronary heart disease
chronic heart failure
sacubitril and valsartan
levosimendan
cardiac function
biochemical marker
